Start-up proposes ‘third way’ to cut US drug prices

Financial Times

12 January 2020 - Alexis Borisy secures $200 million funding for venture aiming to use ‘fast follow’ treatments.

 A serial biotech entrepreneur and investor is launching a company to undercut rivals and try to upend the US drug pricing system, aiming to prove that the market can solve the problem of soaring drug prices that US politicians have tried, but failed, to tackle.

Alexis Borisy is proposing a third way between high-priced branded medicines and cheaper generics: “fast follow” drugs for conditions such as cancer and rare diseases, using alternative but similar active pharmaceutical ingredients as patented drugs.

Read Financial Times article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Pricing